Scarica l'app Stockscreener
61.62
1.25%
0.7375
Vaxcyte Inc Borsa (PCVX) Ultime notizie
PCVX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
How Vaxcyte Inc. (PCVX) Affects Rotational Strategy Timing - Stock Traders Daily
Is It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump? - Yahoo Finance
What is the target price for Vaxcyte Inc stock2026 Momentum Check & AI Forecasted Entry/Exit Points - baoquankhu1.vn
PCVX SEC FilingsVaxcyte, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vaxcyte CAO Sells $180,000 in Company Stock - National Today
Vaxcyte CAO Sells $180,000 in Stock - National Today
Vaxcyte (PCVX) finance chief sells 3,000 shares after option exercise - Stock Titan
Vaxcyte to Present at Annual Healthcare Conference - National Today
Vaxcyte Inc stock: Why its pneumococcal vaccine pipeline draws investor focus - AD HOC NEWS
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Sahm
Elvia Cowan registers 3,000-share sale (PCVX) after option exercise - Stock Titan
Vaxcyte (PCVX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Aberdeen Group plc Increases Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
PCVX.O Technical Analysis & Stock Price Forecast - Intellectia AI
PCVX Should I Buy - Intellectia AI
Insider Sell Alert: Jim Wassil Sells 2,250 Shares of Vaxcyte Inc (PCVX) - GuruFocus
Vaxcyte (PCVX) COO sells 2,250 shares in planned Rule 10b5-1 trades - Stock Titan
James Wassil sells 7,395 PCVX shares (NASDAQ: PCVX) - Stock Titan
Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aug Ideas: Is now the right time to enter Vaxcyte Inc2026 Short Interest & Trade Opportunity Analysis Reports - baoquankhu1.vn
(PCVX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Vaxcyte joins elite club of stocks with RS ratings over 90 - msn.com
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - MarketScreener
Certain Pre-funded warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - marketscreener.com
Certain Restricted Stock Units of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - marketscreener.com
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - MarketScreener
Should Vaxcyte’s (PCVX) Fully Enrolled VAX-31 Phase 3 Trials Prompt a Portfolio Reassessment? - simplywall.st
Vanguard disaggregates holdings; PCVX ownership shown as 0 (PCVX) - stocktitan.net
Portfolio Update: Can Vaxcyte Inc continue delivering strong returns2026 Market WrapUp & Long Hold Capital Preservation Tips - baoquankhu1.vn
Assenagon Asset Management S.A. Increases Position in Vaxcyte, Inc. $PCVX - MarketBeat
Calif. Biotech Firm Vera Taps Vaxcyte Ex-GC As New CLO - Law360
Vaxcyte completes enrollment in two Phase 3 trials for VAX-31 - Investing.com Canada
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults - Investing News Network
Vaxcyte (PCVX) Completes Enrollment for Key Phase 3 Trials - GuruFocus
Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative - simplywall.st
Assessing Vaxcyte (PCVX) Valuation After Strong VAX 31 Phase 1/2 Results In The Lancet - simplywall.st
Responsive Playbooks and the PCVX Inflection - Stock Traders Daily
Vaxcyte Announces Significant Development of First-of-Its-Kind PCV31 - Drug Topics
PCVX PE Ratio & Valuation, Is PCVX Overvalued - Intellectia AI
JPMorgan Chase & Co. Acquires 366,266 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc.: Fundamental Analysis and Financial Ratings | 1PCVX | US92243G1085 - marketscreener.com
Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet - Investing.com Australia
Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCVX) - GuruFocus
Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCV - GuruFocus
Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet By Investing.com - Investing.com South Africa
Vaxcyte (PCVX) Advances VAX-31 Vaccine with Positive Study Resul - GuruFocus
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):